We are breaking new ground in the treatment of digestive diseases

At Perseo pharma our goal is to develop oral enzyme therapies to help patients suffering from digestive diseases

Many people around the world suffer from digestive deficiencies. The cause can be a defective pancreas (exocrine pancreatic insufficiency derived from cystic fibrosis, pancreatitis, pancreatic cancer, and other related diseases) or the consequences of a severe medical treatment (chemotherapy, antibiotics).

Current treatments include oral enzyme therapies. Often, those medicines lack efficiency as enzymes are fragile and once ingested, can quickly lose activity in the harsh gastrointestinal environment. Also, they are rapidly flushed down the GI tract together with food and liquids. What patients must endure is a real pill burden, having to take multiple pills (up to 20) per day and at the same time, due to the rapid flushing, they lose the vital nutrition.

This is where Perseo pharma, a preclinical stage biopharmaceutical company, comes in. We are on the quest to breaking new ground in enzyme therapies. Our goal is to develop a series of innovative patient-centered oral enzyme digestive therapies based on our proprietary nanotechnology platform. The platform can be applied to any enzyme or cocktail of enzymes. This innovative technology protects the enzyme in a nano-shield and binds it specifically to the mucus of the small intestine, where the digestion takes place. Digestion efficiency can therefore be highly improved while the pill burden can be eliminated.

Our pipeline

Therapeutic indication Therapeutic enzyme(s) Development stage
Wave 1 – Digestive therapies
PER301 Exocrine Pancreatic Insufficiency (EPI) Pancreatic Enzyme Replacement Therapy (PERT) with cocktail of lipase, protease, amylase Preclinical
(FiH S2-2023)
PER302 Acquired Lactase Deficiency (ALD) Lactase Preclinical
(FiH S2-2023)
PER303 Phenylketonuria (PKU) Phenylalanine Ammonia Lyase Preclinical
(FiH S1-2024)
PER312 Congenital Sucrase-Isomaltase Deficiency (CSID) Sucrase-Isomaltase Preclinical
(FiH S2-2024)
Wave 2 – Other therapeutic areas
PER100 Oncology Cocktail of enzymes active on tumor metabolism Preclinical
PER200 Lysosomal Storage Diseases Systemic enzyme replacement therapies Research

*FiH: First in Human

Perseo pharma AG was founded in March 2019 in Basel, Switzerland, one of the world-renowned pharma hubs.